---
title: "Top NewcelX Insiders Quietly Make Bold Moves With Fresh Share Purchases"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284676946.md"
description: "NewcelX (NCEL) insiders have made significant share purchases, with Director Samuel Olivier buying 81,818 shares for $224,999 and CSO Michel Revel acquiring 54,545 shares for $149,998. These transactions may indicate confidence in the company's future. Recent updates highlight NCEL-101 as central to its Type 1 diabetes strategy and a collaboration with Eledon for improved graft survival. The stock has seen a year-to-date price increase of 76.32%, with a current market cap of $17.64M, amidst a challenging biotech financing environment."
datetime: "2026-04-30T02:02:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284676946.md)
  - [en](https://longbridge.com/en/news/284676946.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284676946.md)
---

# Top NewcelX Insiders Quietly Make Bold Moves With Fresh Share Purchases

New insider activity at NewcelX ( (NCEL) ) has taken place on April 29, 2026.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

NewcelX has seen notable insider buying activity, with Director Samuel Olivier acquiring 81,818 shares of the company’s stock in a transaction valued at $224,999. In a separate purchase, CSO and Director Michel Revel bought 54,545 shares of NewcelX stock for a total consideration of $149,998. These substantial purchases by key insiders may signal confidence in NewcelX’s prospects and future performance.

**Recent Updates on NCEL stock**

NewcelX shares reacted to the company’s updated investor presentation, which elevates NCEL-101 as the core of its Type 1 diabetes strategy and showcases a collaboration with Eledon that combines stem-cell-derived islet replacement with targeted immune modulation to improve graft survival. Sentiment also reflected the recently detailed premium-priced private placement and access to an equity line, which together extend funding runway for NCEL-101 and the broader pipeline in a tough biotech financing environment, factors likely driving analysts to reassess expectations and valuation assumptions.

**More about NewcelX**

**YTD Price Performance:** 76.32%

**Average Trading Volume:** 39,981

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $17.64M

### Related Stocks

- [NCEL.US](https://longbridge.com/en/quote/NCEL.US.md)
- [ELDN.US](https://longbridge.com/en/quote/ELDN.US.md)
- [NLSPW.US](https://longbridge.com/en/quote/NLSPW.US.md)

## Related News & Research

- [EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug](https://longbridge.com/en/news/284765384.md)
- [NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing | NCEL Stock News](https://longbridge.com/en/news/281357100.md)
- [A Look At UroGen Pharma (URGN) Valuation After New UGN-103 And ZUSDURI Bladder Cancer Data](https://longbridge.com/en/news/286722721.md)
- [Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares](https://longbridge.com/en/news/286950631.md)
- [Zenas BioPharma Insider Bought Shares Worth $1,012,800, According to a Recent SEC Filing](https://longbridge.com/en/news/286872009.md)